Combination of tyrosine kinase inhibitor and HER-2/neu for cancer therapy

Details for Australian Patent Application No. 2005313439 (hide)

Owner GlaxoSmithKline Biologicals s.a.

Inventors Gerard, Catherine Marie Ghislaine; Bruck, Claudine Elvire Marie

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2005313439

PCT Pub. Number WO2006/061253

Priority 0427131.8 10.12.04 GB

Filing date 8 December 2005

Wipo publication date 15 June 2006

International Classifications

A61K 39/00 (2006.01) Medicinal preparations containing antigens or antibodies

A61K 31/517 (2006.01) - ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

5 July 2007 PCT application entered the National Phase

  PCT publication WO2006/061253 Priority application(s): WO2006/061253

7 July 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005313442-Resistance to downy mildew of onion caused by the fungus Peronospora destructor

2005313435-Aqueous binder for mineral fibers